Raises $88.5 Million Series B Financing to Advance Precision Oncology and Targeted Protein Degradation Pipeline | Frontier Medicine
Summary
Funding to Enhance Research and Development of Pipeline, Including Lead Program Targeting Activated KRASG12C Proceeds to Further Accelerate the Development of Foundational Technologies in Chemoproteomics, Covalent Drug Discovery and Machine LearningSOUTH SAN FRANCISCO, Calif. Frontier Medicines Corporation, a precision medicine company seeking to unlock the proteome to advance breakthroughs against otherwise undruggable disease-causing targets, today announced the closing of an $88.5 million Series B financing round. In addition to the lead programs targeting notable cancer drivers, Frontier has identified over 150,000 hotspots on proteins of interest that can fuel further pipeline growth across therapeutic areas and protein degradation.In addition, the company revealed its Scientific Advisory Board (SAB), composed of renowned thought leaders and industry veterans who are an integral part of Frontiers team:Joan S. Brugge, Ph.D. is the director of the Harvard Ludwig Cancer Center and also a Louise Foote Pfeiffer Professor of Cell Biology at Harvard Medical School. His laboratory focuses on understanding the cooperative interactions that conspire to transform human cells.Kevin Koch, Ph.D. is the former chief scientific officer of Array BioPharma and a venture partner with OrbiMed. His expertise includes drug discovery, medicinal chemistry, and pre-clinical development.Frank McCormick, Ph.D., FRS is a professor at the UCSF Helen Diller Family Comprehensive Cancer Center and a world-renowned expert in KRAS biology. The company is deploying its technologies in chemoproteomics, covalent drug discovery, and machine learning to potentially develop groundbreaking medicines for genetically-defined patient populations, starting in cancer.
Funding
Classifications
AskAI Classifications
LabelsLinked Companies
